Ruggeri Loredana, Capanni Marusca, Urbani Elena, Perruccio Katia, Shlomchik Warren D, Tosti Antonella, Posati Sabrina, Rogaia Daniela, Frassoni Francesco, Aversa Franco, Martelli Massimo F, Velardi Andrea
Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
用于治疗白血病的异基因造血移植物所伴随的T细胞可增强植入并介导移植物抗白血病效应。不幸的是，同种异体反应性T细胞也会引发移植物抗宿主病（GVHD）。T细胞清除可预防GVHD，但会增加移植物排斥和白血病复发的风险。在人类移植中，我们发现供体对受体的自然杀伤（NK）细胞同种异体反应性可消除白血病复发和移植物排斥，并保护患者免受GVHD的影响。在小鼠中，移植前输注同种异体反应性NK细胞无需进行高强度预处理并可减轻GVHD。因此，NK细胞同种异体反应性可能为提高异基因造血移植的疗效和安全性提供有力工具。
